Kidswell Bio Corporation

Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebranding in July 2021, maintains a robust pipeline of therapeutic candidates. This includes GND-004, designed for both ophthalmic conditions and oncology, and GND-007, aimed at immunological disorders. Their portfolio also features a range of antibodies being developed for cancer therapies. Further expanding its research, the GBS series encompasses GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for eye-related ailments; GBS-008 for infectious diseases; and GBS-011 for renal conditions. Additionally, Kidswell Bio is progressing GCT-101 for alveolar clefts, GCT-102 for congenital isolated hypoganglionosis, alongside other investigational products addressing ophthalmologic disorders, cerebral palsy, peripheral nerve palsy, fractures, and spinal cord injuries.

Industry

Biotechnology

Sector

Healthcare

Headquarters

JP

CEO

Shinya Kurebayashi

Listed since

Nov 30, 2012

Employees

32